PE20120764A1 - Derivados de isotiazolo-pirimidindiona como moduladores de trpa1 - Google Patents
Derivados de isotiazolo-pirimidindiona como moduladores de trpa1Info
- Publication number
- PE20120764A1 PE20120764A1 PE2011001703A PE2011001703A PE20120764A1 PE 20120764 A1 PE20120764 A1 PE 20120764A1 PE 2011001703 A PE2011001703 A PE 2011001703A PE 2011001703 A PE2011001703 A PE 2011001703A PE 20120764 A1 PE20120764 A1 PE 20120764A1
- Authority
- PE
- Peru
- Prior art keywords
- pyrimidindione
- isothiazolo
- derivatives
- hydroxyl
- alkyl
- Prior art date
Links
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 title 1
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 title 1
- CBFZADDDBQLSPS-UHFFFAOYSA-N [1,2]thiazolo[4,3-d]pyrimidine 2,2-dioxide Chemical class N1=CN=CC2=NS(=O)(=O)C=C21 CBFZADDDBQLSPS-UHFFFAOYSA-N 0.000 title 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical class [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 abstract 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 abstract 3
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical group F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 abstract 1
- -1 ISOTIAZOLE Chemical compound 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 abstract 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 abstract 1
- 229930192474 thiophene Natural products 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
REFERIDA A UN COMPUESTO DE FORMULA I, DONDE Y y Z SON CADA UNO S, N; R1 Y R2 SON CADA UNO H, HIDROXILO, ALQUILO, HALOALQUILO, ALQUENILO, CICLOALQUILO, ENTRE OTROS; R3 ES H, HIDROXILO, ALQUILO, HALOALQUILO, ALQUENILO, ENTRE OTROS; L ES UN LIGADOR -CO-, -NH-, ENTRE OTROS; U ES ARILO SUSTITUIDO O NO, TALES COMO TIAZOL, ISOTIAZOL, OXAZOL, ISOXAZOL, TIOFENO, ENTRE OTROS; V ES H, CIANO, NITRO, HALOGENO, HIDROXILO, ALQUILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-(5,7-DIMETIL-4,6-DIOXO-4,5,6,7-TETRAHIDRO[1,2]TIAZOLO[3,4-d]PIRIMIDIN-3-IL)-N-{4-[3-(TRIFLUOROMETIL)FENIL]-1,3-TIAZOL-2-IL}ACETAMIDA; N-{4-[4-(DIFLUOROMETOXI)-3-FLUOROFENIL]-1,3-TIAZOL-2-IL}-2-(5,7-DIMETIL-4,6-DIOXO-4,5,6,7-TETRAHIDRO[1,2]TIAZOLO[5,4-d]PIRIMIDIN-3-IL)ACETAMIDA.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN665MU2009 | 2009-03-23 | ||
| US17135509P | 2009-04-21 | 2009-04-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20120764A1 true PE20120764A1 (es) | 2012-06-27 |
Family
ID=42236291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011001703A PE20120764A1 (es) | 2009-03-23 | 2010-03-22 | Derivados de isotiazolo-pirimidindiona como moduladores de trpa1 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8575178B2 (es) |
| EP (1) | EP2411397B1 (es) |
| JP (1) | JP2012521405A (es) |
| KR (1) | KR20120001746A (es) |
| CN (1) | CN102395592A (es) |
| AP (1) | AP2011005888A0 (es) |
| AU (1) | AU2010227224A1 (es) |
| BR (1) | BRPI1009372A2 (es) |
| CA (1) | CA2756534A1 (es) |
| DK (1) | DK2411397T3 (es) |
| EA (1) | EA201190191A1 (es) |
| ES (1) | ES2424340T3 (es) |
| IL (1) | IL215179A0 (es) |
| MX (1) | MX2011009821A (es) |
| PE (1) | PE20120764A1 (es) |
| PL (1) | PL2411397T3 (es) |
| PT (1) | PT2411397E (es) |
| SG (2) | SG184766A1 (es) |
| SI (1) | SI2411397T1 (es) |
| UA (1) | UA107342C2 (es) |
| WO (1) | WO2010109328A1 (es) |
| ZA (1) | ZA201107646B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2411393B1 (en) | 2009-03-23 | 2014-01-22 | Glenmark Pharmaceuticals S.A. | Fused pyrimidine-dione derivatives as trpa1 modulators |
| SI2411395T1 (sl) | 2009-03-23 | 2013-07-31 | Glenmark Pharmaceuticals S.A. | Furopirimidindionski derivati kot TRPA1 modulatorji |
| AU2011346763B2 (en) * | 2010-12-20 | 2016-01-07 | Glenmark Pharmaceuticals S.A. | 2-amino-4-arylthiazole compounds as TRPA1 antagonists |
| EP2520566A1 (en) | 2011-05-06 | 2012-11-07 | Orion Corporation | New Pharmaceutical Compounds |
| CA2836856A1 (en) * | 2011-06-13 | 2012-12-20 | Glenmark Pharmaceuticals, S.A. | Treatment of respiratory disorders using trpa1 antagonists |
| BR112013031820A2 (pt) | 2011-06-22 | 2016-12-13 | Glenmark Pharmaceutical S A | composições farmacêuticas, incluindo para administração oral e por inalação, usos de quantidade sinergicamente eficaz de antagonista trpa1 e métodos para tratar distúrbios respiratórios e para melhorar a função pulmonar |
| WO2012176105A1 (en) | 2011-06-22 | 2012-12-27 | Glenmark Pharmaceuticals Sa | Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist |
| WO2013014597A1 (en) | 2011-07-25 | 2013-01-31 | Glenmark Pharmaceuticals Sa | Pharmaceutical composition comprising a trpa1 antagonist and a steroid |
| TWI640519B (zh) * | 2011-11-29 | 2018-11-11 | 泰緯生命科技股份有限公司 | Ｈｅｃ１活性調控因子及其調節方法 |
| CA2857109A1 (en) * | 2011-12-05 | 2013-06-13 | Glenmark Pharmaceuticals S.A. | Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent |
| AU2013273118B2 (en) | 2012-06-08 | 2015-11-05 | Glenmark Pharmaceuticals S.A. | Amides of 2-amino-4-arylthiazole compounds and their salts |
| PL2903965T3 (pl) | 2012-10-01 | 2017-08-31 | Orion Corporation | Pochodne n-prop-2-ynylokarboksamidu i ich zastosowanie jako antagonistów trpa1 |
| JP2016504988A (ja) | 2012-11-14 | 2016-02-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | イミダゾピリジン誘導体 |
| AU2014282762B2 (en) | 2013-06-20 | 2016-11-10 | Ichnos Sciences SA | Nanoparticulate formulation comprising a TRPA1 antagonist |
| MX2016004741A (es) | 2013-10-15 | 2016-07-26 | Glenmark Pharmaceuticals Sa | Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico. |
| WO2015155306A1 (en) * | 2014-04-11 | 2015-10-15 | Almirall, S.A. | New trpa1 antagonists |
| WO2016042501A1 (en) | 2014-09-16 | 2016-03-24 | Glenmark Pharmaceuticals S.A. | Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain |
| WO2017060488A1 (en) | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
| WO2017064068A1 (en) | 2015-10-14 | 2017-04-20 | Almirall, S.A. | New trpa1 antagonists |
| WO2018233648A1 (zh) * | 2017-06-21 | 2018-12-27 | 南京明德新药研发股份有限公司 | 作为TLR8激动剂的异噻唑并[4,3-d]嘧啶-5,7-二胺衍生物 |
| CN112794860B (zh) * | 2021-03-24 | 2021-06-29 | 上海肇钰医药科技有限公司 | 噁唑嘧啶酮酰胺类化合物或其可药用盐，制备方法及用途 |
| CN114656480B (zh) * | 2022-04-27 | 2024-01-26 | 成都施贝康生物医药科技有限公司 | 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途 |
| WO2025264860A2 (en) | 2024-06-18 | 2025-12-26 | Yale University | Methods of treating post-covid airway disease |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2248231A1 (de) | 1972-10-02 | 1974-04-11 | Basf Ag | 3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine |
| SE9701398D0 (sv) | 1997-04-15 | 1997-04-15 | Astra Pharma Prod | Novel compounds |
| ES2193839B1 (es) | 2001-06-22 | 2005-02-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de 6-fenildihidropirrolpirimidindiona. |
| WO2004014916A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
| US7465581B2 (en) | 2002-12-18 | 2008-12-16 | The Scripps Research Institute | ANKTM1, a cold-activated TRP-like channel expressed in nociceptive neurons |
| SE0300119D0 (sv) * | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
| WO2005077959A1 (en) | 2004-02-11 | 2005-08-25 | Smithkline Beecham Corporation | Pth agonists |
| US20070196866A1 (en) | 2004-03-13 | 2007-08-23 | Irm Llc | Modulators of ion channel trpa1 |
| EP1847541A4 (en) | 2005-02-03 | 2009-12-30 | Takeda Pharmaceutical | CONDENSED PYRIMIDINE DERIVATIVE AND USE THEREOF |
| AU2006327181A1 (en) * | 2005-12-22 | 2007-06-28 | Hydra Biosciences, Inc. | TRPA1 inhibitors for treating pain |
| TW200800997A (en) | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
| WO2008094909A2 (en) | 2007-01-29 | 2008-08-07 | Xenon Pharmaceuticals Inc. | Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions |
| WO2009002933A1 (en) * | 2007-06-22 | 2008-12-31 | Hydra Biosciences, Inc. | Methods and compositions for treating disorders |
| WO2009158719A2 (en) | 2008-06-27 | 2009-12-30 | Hydra Biosciences, Inc. | Methods and compositions for treating disorders |
-
2010
- 2010-03-22 MX MX2011009821A patent/MX2011009821A/es unknown
- 2010-03-22 PE PE2011001703A patent/PE20120764A1/es not_active Application Discontinuation
- 2010-03-22 WO PCT/IB2010/000834 patent/WO2010109328A1/en not_active Ceased
- 2010-03-22 SG SG2012069464A patent/SG184766A1/en unknown
- 2010-03-22 JP JP2012501411A patent/JP2012521405A/ja not_active Withdrawn
- 2010-03-22 DK DK10716049.1T patent/DK2411397T3/da active
- 2010-03-22 KR KR1020117023383A patent/KR20120001746A/ko not_active Withdrawn
- 2010-03-22 SI SI201030232T patent/SI2411397T1/sl unknown
- 2010-03-22 AP AP2011005888A patent/AP2011005888A0/xx unknown
- 2010-03-22 PL PL10716049T patent/PL2411397T3/pl unknown
- 2010-03-22 BR BRPI1009372A patent/BRPI1009372A2/pt not_active IP Right Cessation
- 2010-03-22 US US13/257,241 patent/US8575178B2/en not_active Expired - Fee Related
- 2010-03-22 PT PT107160491T patent/PT2411397E/pt unknown
- 2010-03-22 CN CN2010800168801A patent/CN102395592A/zh active Pending
- 2010-03-22 EP EP10716049.1A patent/EP2411397B1/en not_active Not-in-force
- 2010-03-22 SG SG2011066495A patent/SG174403A1/en unknown
- 2010-03-22 CA CA2756534A patent/CA2756534A1/en not_active Abandoned
- 2010-03-22 AU AU2010227224A patent/AU2010227224A1/en not_active Abandoned
- 2010-03-22 EA EA201190191A patent/EA201190191A1/ru unknown
- 2010-03-22 ES ES10716049T patent/ES2424340T3/es active Active
- 2010-03-23 UA UAA201111149A patent/UA107342C2/ru unknown
-
2011
- 2011-09-15 IL IL215179A patent/IL215179A0/en unknown
- 2011-10-19 ZA ZA2011/07646A patent/ZA201107646B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010227224A1 (en) | 2011-09-29 |
| US20120010223A1 (en) | 2012-01-12 |
| CA2756534A1 (en) | 2010-09-30 |
| PL2411397T3 (pl) | 2013-10-31 |
| PT2411397E (pt) | 2013-06-06 |
| WO2010109328A1 (en) | 2010-09-30 |
| AP2011005888A0 (en) | 2011-10-31 |
| EP2411397B1 (en) | 2013-05-29 |
| MX2011009821A (es) | 2012-01-25 |
| BRPI1009372A2 (pt) | 2016-05-31 |
| ZA201107646B (en) | 2012-06-25 |
| SG174403A1 (en) | 2011-10-28 |
| SI2411397T1 (sl) | 2013-07-31 |
| UA107342C2 (en) | 2014-12-25 |
| EP2411397A1 (en) | 2012-02-01 |
| US8575178B2 (en) | 2013-11-05 |
| KR20120001746A (ko) | 2012-01-04 |
| DK2411397T3 (da) | 2013-08-05 |
| IL215179A0 (en) | 2011-12-29 |
| CN102395592A (zh) | 2012-03-28 |
| JP2012521405A (ja) | 2012-09-13 |
| SG184766A1 (en) | 2012-10-30 |
| ES2424340T3 (es) | 2013-10-01 |
| EA201190191A1 (ru) | 2012-11-30 |
| AU2010227224A2 (en) | 2011-10-27 |
| HK1166081A1 (en) | 2012-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120764A1 (es) | Derivados de isotiazolo-pirimidindiona como moduladores de trpa1 | |
| PE20021152A1 (es) | Derivados de oxazol como agonistas de receptores activados por proliferacion de peroxisoma | |
| PE20081398A1 (es) | Derivados de oxadiazol como agonistas del receptor sensible a 1-fosfato de esfingosina (s1p1) | |
| PE20121440A1 (es) | Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurologicos | |
| PE20131153A1 (es) | Inhibidores de la tirosina-quinasa de bruton | |
| PE20091952A1 (es) | Compuestos de tiazole y oxazole de sulfonamida de benzeno | |
| PE20120775A1 (es) | Derivados de tienopirimidindiona como moduladores de trpa1 | |
| PE20090290A1 (es) | Derivados de pirrolopiridina como inhibidores de bace | |
| AR079224A1 (es) | Compuestos insecticidas basados en derivados de isoxazolina | |
| NI200900139A (es) | Derivados de espirocromanona sustituidos como inhibidores de acc. | |
| PE20071156A1 (es) | COMPUESTOS DERIVADOS DE 4,5,6,7-TETRAHIDRO-1H-INDAZOL COMO POTENCIADORES DEL RECEPTOR DEL ACIDO a-AMINO-3-HIDROXI-5-METILISOXAZOL-4-PROPIONICO (AMPA) | |
| PE20140623A1 (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2 | |
| PE20130382A1 (es) | Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a | |
| AR086587A1 (es) | Compuestos insecticidas | |
| PE20121047A1 (es) | Derivados de tiazolilpiperidina como fungicidas | |
| PE20080188A1 (es) | Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol | |
| PE20141529A1 (es) | Derivados de biciclo [3,2,1] octilamida y sus usos | |
| PE20091068A1 (es) | Compuestos pirrolo[3,2-d]pirimidina y su uso como inhibidores de quinasa pi3 y quinasa mtor | |
| PE20140207A1 (es) | Composiciones y metodos para modular el fxr | |
| PE20141588A1 (es) | Nuevos derivados de [1,2,3]triazolo[4,5-d]pirimidina como agonistas del receptor de canabinoides 2 | |
| PE20050417A1 (es) | Compuestos que modulan la actividad de ppar y procedimientos de preparacion | |
| CO6180435A2 (es) | Amidas de diazabicicloalcanos selectivas del subtipo del receptor nicotinico de acetilcolina | |
| PE20121500A1 (es) | 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2 | |
| PE20040190A1 (es) | Tiazoles y oxazoles sustituidos que modulan la actividad de ppar | |
| PE20091339A1 (es) | Derivados de oxadiazol con actividad sobre receptores s1p1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |